Alam Abdulkader, Voronovich Zoya, Carley Joseph A
Departments of Psychiatry and Medicine (Dr Alam), University of Pittsburgh School of Medicine (Ms Voronovich), Pittsburgh, Pennsylvania; and University of Alabama School of Medicine, Birmingham (Dr Carley).
Prim Care Companion CNS Disord. 2013;15(5). doi: 10.4088/PCC.13r01525. Epub 2013 Oct 10.
To review the literature examining the use of mirtazapine with an emphasis on its therapeutic benefits for psychiatric patients with comorbid medical conditions.
MEDLINE, PsycINFO, Global Health, and AGRICOLA were searched using the terms mirtazapine OR Remeron. Limits were English language, human, year 1980-2012, treatment and prevention, and therapy.
Two hundred ninety-three articles were identified.
Identified articles were reviewed with a focus on indications and therapeutic benefits in patients with medical comorbidities.
Mirtazapine is an effective antidepressant with unique mechanisms of action. It is characterized by a relatively rapid onset of action, high response and remission rates, a favorable side-effect profile, and several unique therapeutic benefits over other antidepressants. Mirtazapine has also shown promise in treating some medical disorders, including neurologic conditions, and ameliorating some of the associated debilitating symptoms of weight loss, insomnia, and postoperative nausea and vomiting.
Mirtazapine offers clinicians multiple therapeutic advantages especially when treating patients with comorbid medical illness.
回顾关于米氮平使用情况的文献，重点关注其对合并躯体疾病的精神科患者的治疗益处。
使用米氮平或瑞美隆作为检索词，检索MEDLINE、PsycINFO、全球健康数据库和农业与生命科学数据库。检索限制为英文文献、人类研究、1980 - 2012年、治疗与预防以及疗法相关文献。
共识别出293篇文章。
对识别出的文章进行回顾，重点关注合并躯体疾病患者的适应证和治疗益处。
米氮平是一种具有独特作用机制的有效抗抑郁药。其特点是起效相对较快、有效率和缓解率高、副作用较小，且与其他抗抑郁药相比具有一些独特的治疗益处。米氮平在治疗某些躯体疾病（包括神经系统疾病）以及改善一些相关的衰弱症状（如体重减轻、失眠和术后恶心呕吐）方面也显示出前景。
米氮平为临床医生提供了多种治疗优势，尤其是在治疗合并躯体疾病的患者时。
